Generic drugmakers have complained to the European Patent Office over the body’s surprise restoration of a patent for Merck’s blockbuster drug Fosamax.

The generic groups are asking for a review on whether the US drugmaker “misled” the patent-granting authority for Europe or whether public interest was best served with the patent restoration of Fosamax.